Literature DB >> 8622032

Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials.

S El-Sayed1, N Nelson.   

Abstract

PURPOSE: Using the technique of meta-analysis, we aim to illustrate the potential benefit, or lack of it, in adding chemotherapy to locoregional definitive treatment in a prospective randomized setting. PATIENTS AND METHODS: Mantel-Haenszel summary analyses were used to test 42 prospective and properly randomized trials for statistically significant differences in the proportion with side effects and in the proportion with response to treatment between the experimental treatment arm (including chemotherapy) and control arm (local definitive treatment only) of the study. Summarized estimates of relative risks of side effects and relative proportions of positive responses were obtained using the summarizing options in PROC FREQ in the SAS computer package. In 25 of 42 studies, sufficient survival information was available to estimate the effect of chemotherapy on the rate of dying per person per unit of time.
RESULTS: Chemotherapy, when added to local definitive treatment, was found to increase toxicity. This increase is statistically significant. The relative proportion of side effects was 2.17, with a 95% confidence interval of 1.84 to 2.56 and P less than .001. Addition of chemotherapy to local treatment has reduced the mortality rate for treated patients by 11% in the total group (all 25 studies), with a 95% confidence interval of 1% to 19%. This reduction means that at the time 50% of patients in the control arm were still alive, 54% of patients who received chemotherapy would be expected to be alive. Concurrent treatment (11 studies) has reduced the mortality rate by 22%, with a 95% confidence interval of 8% to 33%, which means that at the time 50% of patients in the control arm were still alive, 58% of patients who received chemotherapy would be expected to be alive.
CONCLUSION: Addition of chemotherapy to local definitive treatment has significantly increased the morbidity of treatment as well as the chance of initial tumor response and local control. A statistically significant improvement in survival was found for the simultaneous use of chemotherapy and local definitive treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622032     DOI: 10.1200/JCO.1996.14.3.838

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  44 in total

Review 1.  Concurrent chemoradiotherapy in head and neck cancer.

Authors:  S G Urba
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

Review 2.  Treatment of advanced head and neck cancer with intra-arterial cisplatin and concurrent radiation therapy: the 'RADPLAT' protocol.

Authors:  P Kumar; K T Robbins
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

Review 3.  Fortnightly review: oral cancer.

Authors:  J M Zakrzewska
Journal:  BMJ       Date:  1999-04-17

Review 4.  Impact of anemia in patients with head and neck cancer treated with radiation therapy.

Authors:  Kenneth Hu; Louis B Harrison
Journal:  Curr Treat Options Oncol       Date:  2005-01

5.  Radiotherapy for head and neck cancer.

Authors:  Shyh-An Yeh
Journal:  Semin Plast Surg       Date:  2010-05       Impact factor: 2.314

Review 6.  [Oncology '96].

Authors:  F Hartmann; M Pfreundschuh
Journal:  Med Klin (Munich)       Date:  1997-02-15

7.  Role of Single-Agent Methotrexate as a Neoadjuvant Chemotherapy in Oral Cavity Cancers.

Authors:  Amol Deshpande; Vipul V Nandu; Jaideep Jadhav
Journal:  Indian J Surg Oncol       Date:  2018-12-19

8.  Two- vs three-drug combination chemotherapy in advanced or recurrent head and neck cancer: a single institution experience of 361 patients.

Authors:  V R Pai; A T Mazumdar; C D Deshmukh; A V Bakshi; D M Parikh; P M Parikh; R C Mistry; K A Pathak; A K D'Cruz
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

9.  Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study.

Authors:  George Fountzilas; Elisabeta Ciuleanu; Urania Dafni; George Plataniotis; Anna Kalogera-Fountzila; Epaminontas Samantas; Eleni Athanassiou; John Tzitzikas; Tudor Ciuleanu; Angelos Nikolaou; Panayiotis Pantelakos; Thomas Zaraboukas; Nikolaos Zamboglou; John Daniilidis; Nicolas Ghilezan
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

10.  Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer.

Authors:  Wen-Yen Huang; Yee-Min Jen; Chang-Ming Chen; Yu-Fu Su; Chun-Shu Lin; Yaoh-Shiang Lin; Ying-Nan Chang; Hsing-Lung Chao; Kuen-Tze Lin; Li-Ping Chang
Journal:  Radiat Oncol       Date:  2010-05-15       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.